Ποια είναι η τιμή για Molecular Partners AG (MOLN)

Η τιμή για Molecular Partners AG (MOLN) είναι $4.43

Ποια είναι η κεφαλαιοποίηση αγοράς για Molecular Partners AG (MOLN)

Η κεφαλαιοποίηση αγοράς για Molecular Partners AG (MOLN) είναι $166.36M

Molecular Partners AG (MOLN) Τιμή και Κεφαλαιοποίηση Αγοράς

Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.

Η τιμή για MOLN	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$137,359 $166.36M	NVDA	$5.152T	+3,097,112.86%
$120,951 $166.36M	AAPL	$4.537T	+2,727,149.72%
$111,129 $166.36M	GOOG	$4.169T	+2,505,668.75%
$97,100.26 $166.36M	MSFT	$3.642T	+2,189,354.17%
$74,769.71 $166.36M	AMZN	$2.805T	+1,685,836.26%

Η τιμή για MOLN

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$137,359 $166.36M